160 related articles for article (PubMed ID: 34439386)
21. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
[TBL] [Abstract][Full Text] [Related]
22. Surgical Outcomes and Prognostic Factors of G3 Pancreatic Neuroendocrine Carcinomas: A Consecutive Analysis Based on Previous Study Results.
Luo X; Yang M; Tian B; Liu X; Duan K; Zhang Y
J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683561
[TBL] [Abstract][Full Text] [Related]
23. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment.
Alan O; Telli TA; Basoğlu T; Arikan R; Demircan NC; Ercelep O; Bozkurt S; Atasoy BM; Dane F; Yumuk PF
Clin Neurol Neurosurg; 2020 Sep; 196():105976. PubMed ID: 32531614
[TBL] [Abstract][Full Text] [Related]
25. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
Angerilli V; Sabella G; Simbolo M; Lagano V; Centonze G; Gentili M; Mangogna A; Coppa J; Munari G; Businello G; Borga C; Schiavi F; Pusceddu S; Leporati R; Oldani S; Fassan M; Milione M
Br J Cancer; 2024 May; ():. PubMed ID: 38729995
[TBL] [Abstract][Full Text] [Related]
28. Inflammation as a validated prognostic determinant in carcinoma of unknown primary site.
Mohamed Z; Pinato DJ; Mauri FA; Chen KW; Chang PM; Sharma R
Br J Cancer; 2014 Jan; 110(1):208-13. PubMed ID: 24169348
[TBL] [Abstract][Full Text] [Related]
29. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours.
Zou J; Li Q; Kou F; Zhu Y; Lu M; Li J; Lu Z; Shen L
Curr Oncol; 2019 Feb; 26(1):e30-e38. PubMed ID: 30853807
[TBL] [Abstract][Full Text] [Related]
31. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.
Sorbye H; Welin S; Langer SW; Vestermark LW; Holt N; Osterlund P; Dueland S; Hofsli E; Guren MG; Ohrling K; Birkemeyer E; Thiis-Evensen E; Biagini M; Gronbaek H; Soveri LM; Olsen IH; Federspiel B; Assmus J; Janson ET; Knigge U
Ann Oncol; 2013 Jan; 24(1):152-60. PubMed ID: 22967994
[TBL] [Abstract][Full Text] [Related]
32. Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study.
Akdag G; Alan Ö; Dogan A; Yildirim S; Kinikoglu O; Batu A; Kudu E; Geçmen GG; Isik D; Sever ON; Odabas H; Yildirim ME; Turan N
Heliyon; 2024 Feb; 10(3):e25029. PubMed ID: 38317875
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence?
Helpap B; Köllermann J
Virchows Arch; 2001 Jan; 438(1):86-91. PubMed ID: 11213840
[TBL] [Abstract][Full Text] [Related]
36. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
[TBL] [Abstract][Full Text] [Related]
37. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
38. Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma.
Azoulay A; Cros J; Vullierme MP; de Mestier L; Couvelard A; Hentic O; Ruszniewski P; Sauvanet A; Vilgrain V; Ronot M
Diagn Interv Imaging; 2020 Dec; 101(12):821-830. PubMed ID: 32709455
[TBL] [Abstract][Full Text] [Related]
39. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients.
Stangl-Kremser J; Mari A; Suarez-Ibarrola R; D'Andrea D; Korn SM; Pones M; Kramer G; Karakiewicz P; Enikeev DV; Glybochko PV; Briganti A; Shariat SF
Urol Oncol; 2020 Jun; 38(6):600.e9-600.e15. PubMed ID: 31953003
[TBL] [Abstract][Full Text] [Related]
40. Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers.
Boo YJ; Park SS; Kim JH; Mok YJ; Kim SJ; Kim CS
J Surg Oncol; 2007 Feb; 95(2):110-7. PubMed ID: 17066436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
